Analyzing OmniAb (NASDAQ:OABI) and Qiagen (NYSE:QGEN)

OmniAb (NASDAQ:OABI) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Volatility and Risk

OmniAb has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Profitability

This table compares OmniAb and Qiagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Qiagen	19.49%	14.47%	8.34%

Valuation and Earnings

This table compares OmniAb and Qiagen”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67 million	37.77	-$64.78 million	($0.36)	-13.53
Qiagen	$2.10 billion	4.39	$424.88 million	$1.95	22.94

Qiagen has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for OmniAb and Qiagen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1	0	2	0	2.33
Qiagen	0	9	4	1	2.43

OmniAb currently has a consensus price target of $11.00, indicating a potential upside of 125.87%. Qiagen has a consensus price target of $43.51, indicating a potential downside of 2.75%. Given OmniAb’s higher possible upside, research analysts plainly believe OmniAb is more favorable than Qiagen.

Institutional and Insider Ownership

72.1% of OmniAb shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 9.8% of OmniAb shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Qiagen beats OmniAb on 11 of the 15 factors compared between the two stocks.

About OmniAb

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.